Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

The early results showed that 15 of 41 evaluable patients had objective responses and 32 had stable disease with the ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

Rio Tinto and Glencore previously held deal talks in late 2024, but they ended over issues including valuation, the chief ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...